Shire, AbbVie Lay Out Competing Visions Ahead Of Expected New Offer
Shire lays out rationale for remaining independent so it can continue pursuing growth strategy begun by CEO Ornskov, on the job since May 2013. AbbVie tries to argue that it is driven by factors other than tax benefits, and Wall Street suspects a higher bid to buy Shire is in the offing.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.